Eli Lilly est completando los ensayos de fase III Si todo avanza segn lo previsto, la Administracin de Alimentos y Medicamentos (FDA) debera aprobar el frmaco y este podra comercializarse a finales de 2026 o principios de 2027 , segn los plazos observados en otros medicamentos de la misma categora
The implementation nightmare: TMS
ACT 2: What Insurance Coverage Will Actually Look Like The second layer of the access problem is insurance, and the precedent is genuinely discouraging
The two medications have different dose schedules, different side-effect profiles, and different insurance coverage pathways
This article examines what the available evidence shows, why weight loss medicines can trigger hair changes, and when to seek professional advice
When you eat a surplus, your body decides where the extra energy goes based on a stack of hormonal signals